Cresco Labs Posts Growth and Cash Flow Despite $15 Million Loss

By Olivia Hart

What did Cresco Labs report in Q3 2026?

Cresco Labs reported third-quarter 2026 revenue of $173 million, up 5% year over year, and free cash flow of $21 million. The company also recorded a $15 million net loss, combining positive cash generation with an accounting loss.

CEO Charlie Bachtell said: “Q3 delivered revenue of $173 million, up 5% year-over-year, and $26 million in operating cash flow, converting over 60% of Adjusted EBITDA into free cash flow.” His statement emphasized revenue, operating cash flow and cash conversion, but did not address the net loss, debt or acquisition costs.

Takeaway: The quarter generated cash, but did not resolve the gap between cash performance and shareholder profitability.

How profitable were the operations?

Cresco Labs reported the following results for the quarter:

• Gross profit totaled $79 million.
• Adjusted gross profit reached $81 million, representing a 46.8% margin.
• Adjusted EBITDA was $35 million, equal to a 20.2% margin.
• Operating cash flow totaled $26 million.

Selling, general and administrative expense was $58 million, or 33.4% of revenue. Adjusted SG&A was $54 million, or 31.3%. Cresco Labs attributed the difference primarily to one-time and nonrecurring costs associated with acquisitions, uplisting preparation and potential federal reform.

Free cash flow reached $21 million, which Cresco said represented the conversion of more than 60% of adjusted EBITDA. The company’s results therefore provide evidence of operating resilience, although that assessment carries a caveat: the disclosure did not provide a complete reconciliation of all adjustments or their cash impact.

Takeaway: Cash conversion was strong, while the adjustments leave investors comparing two versions of profitability.

What does the balance sheet show?

Cresco Labs ended the quarter with $76 million in cash, cash equivalents and restricted cash. It also carried $454 million in long-term notes and loans payable, nearly six times the reported cash balance.

Restricted cash was included in the $76 million, and Cresco did not disclose the amount. Its results also did not specify maturities, interest rates or covenants, leaving the timing of repayment pressure unquantified.

Takeaway: Cash generation supported the quarter, but leverage remains Cresco’s clearest financial constraint.

What changed across the business?

Cresco Labs said it completed an acquisition, improved cultivation and ramped operations in a new state. It also retained leading share positions in several large cannabis markets, according to the company.

The disclosure did not identify the acquired business, the new state or the markets, and it supplied no market-share figures. Those omissions prevent investors from determining how much growth came from the transaction, existing operations or the new state.

Shareholders approved resolutions intended to simplify Cresco’s corporate structure and better align the company with the U.S. investor base. Cresco did not specify the resolutions or their implementation timetable, so the intended benefits remain unquantified.

Takeaway: The operating expansion is tangible, but the acquisition and structural changes remain too poorly defined for investors to assess.

Does federal reform drive the plan?

Management emphasized that Cresco’s operating plan does not depend on a specific federal reform timetable. The company instead placed greater emphasis on brand performance, retail execution through Sunnyside, disciplined expenses and cash generation.

The plan therefore offers no promised reform catalyst. Cresco also did not quantify what an earlier timetable could mean for revenue or costs, including the potential federal reform costs cited in its adjusted SG&A discussion.

Takeaway: Cresco’s case rests on execution it controls, not on an unspecified federal deadline.

What must Cresco prove next?

Cresco Labs said its next phase depends on integrating the recent transaction, sustaining cultivation improvements and maintaining margins in a competitive, heavily regulated market. Its reported 5% revenue growth and positive free cash flow support the resilience argument, while the $15 million net loss and $454 million in notes and loans payable weigh against it.

Investors should watch integration costs, cultivation gains, Sunnyside performance, gaps between adjusted and reported profit, and continued cash generation. Without acquisition terms and a debt schedule, neither the durability of the $21 million free cash flow nor Cresco’s balance-sheet headroom can be sized.

Takeaway: Cresco must turn operational gains into durable margins before its cash-flow story can carry more weight.